Cadila Healthcare is seeking shareholders’ nod for raising upto Rs 10,000 crore from the capital markets by issuing equity shares, including instruments such as convertible bonds/debentures through qualified institutional placement, to capitalise on the organic and inorganic growth opportunities available in the pharma sector.
While no specific instrument of securities were identified, the board might opt for an ‘appropriate instrument in the best interests of the company’. The resolution seeks approval of shareholders to offer equity shares in one or more tranches to investors, inter alia through QIP by way of private placement.
Cadila Healthcare operates in areas of active pharmaceutical ingredients (API) to formulations, and animal health products to cosmeceuticals.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1619.95 |
| Dr. Reddys Lab | 1315.85 |
| Cipla | 1294.75 |
| Zydus Lifesciences | 927.15 |
| Lupin | 2296.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: